Generic Name:
deucravacitinib
Project Status:
Active
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
Bristol-Myers Squibb Company
Brand Name:
Sotyktu
Project Line:
Reimbursement Review
Project Number:
SR0756-000
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
The treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.